The JPMorgan Healthcare Conference lacked a big pharma deal this week, but executives and investors told Axios Pro they still expect a meaningful biotech rebound in 2026.
Why it matters: Because the San Francisco conference often sets the tone for the year, a good readout is crucial to investors and dealmakers alike.
